A Study of LY3039478 in Participants With Advanced Cancer
Status:
Completed
Trial end date:
2018-06-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find a recommended dose level of LY3039478 that can safely be
taken by participants with advanced cancer or cancer that has spread to other parts of the
body, including but not limited to lymphoma. The study will also explore changes to various
markers in blood cells and tissue. Finally, the study will help to document any tumor
activity this drug may have.